Multinational pharmaceutical companies released 2016 report card, and Johnson & Johnson ranked first!

Source: New Year's weather of cypress blue 2017-2-17, and it's time to summarize and count the past year At present, the major multinational pharmaceutical companies have successively released 2016 financial statements What's the revenue of multinational pharmaceutical giants in the past year? What surprises do they bring us? ▍ in 2016, the performance was generally improved Cypress blue sorted out some multinational pharmaceutical enterprises that had published the 2016 financial report It was found that although there are still some pharmaceutical enterprises that have not published the 2016 performance, the published performance of various multinational pharmaceutical enterprises in 2016 was generally improved, and the revenue in 2016 reached more than 10 billion US dollars In the past, Pfizer, Roche and Novartis have basically led the top three multinational pharmaceutical companies However, according to the published financial statements, it seems that there is no suspense that Johnson & Johnson will be at the top of the list in 2016 According to the financial report of Johnson & Johnson, its revenue in 2016 reached US $71.89 billion, far surpassing Pfizer, Roche and Novartis, which are temporarily ranked second, third and fourth, and its competitive strength can not be underestimated In addition, multinational pharmaceutical companies with revenue growth rate of more than 10% in 2016 include Pfizer, Aberdeen, BMS and Xinji Among them, Xinji is a new member of the $10 billion club The sales of its star anti-tumor drug lenalidomide reached $6.974 billion in 2016, and the company's annual revenue reached $11.185 billion, a year-on-year increase of 22.11% Its ranking rose sharply, becoming a rising star among multinational pharmaceutical enterprises The following is the revenue of some multinational pharmaceutical enterprises in 2016: (source: 2016 financial statements of various pharmaceutical enterprises, excluding those not yet published) ▍ multinational pharmaceutical enterprises are optimistic about the Chinese market In 2016, a large number of multinational pharmaceutical companies experienced business adjustment such as separation of non core sectors, which resulted in their performance generally improved in 2016 From the above data chart, it can be shown intuitively The emerging market, represented by China, has not only become a favored place for multinational pharmaceutical companies, but also provides them with rich profits and greater development space According to the financial data of several multinational pharmaceutical giants in 2016, China's market has become an indispensable part of promoting enterprise performance For example, AstraZeneca's performance in mature markets such as the United States, Europe, Japan and Canada has declined across the board, while it has made amazing performance in emerging markets (including China, Brazil, India, Mexico, Russia and Turkey) In particular, the sales revenue of the Chinese market has reached 2.636 billion US dollars, accounting for 45% of the whole emerging market, which has become a strong support for AstraZeneca's global performance IMS has issued an industry report, predicting that the growth gap between the mature market and the emerging drug market will continue to increase in the next few years According to the report, by 2018, emerging pharmaceutical markets are expected to account for 1 / 3 of the global market value (in line with the U.S market) and contribute nearly 60% to the growth of market value (excluding rebate and discount) The focus of global market growth potential has been significantly biased towards emerging pharmaceutical markets In addition, the accelerated approval of new drugs in China has also brought new business opportunities to multinational pharmaceutical enterprises In an interview with the media, a senior executive of a multinational pharmaceutical company said that it usually takes 5-8 years for foreign new drugs to enter China, resulting in a large number of new drug approvals lagging behind After the acceleration, the accumulated new drugs that did not enter the Chinese market can be introduced quickly, becoming a new market growth point for enterprises ▍ Chinese pharmaceutical companies are also actively "going global" In recent years, while multinational pharmaceutical companies are increasing their investment in China, some powerful local pharmaceutical companies are also extending their tentacles overseas, actively arranging overseas investment to take the lead in the future international competition Recently, Danning tablet, a key product of Shanghai Hehuang Pharmaceutical Co., Ltd., was approved by the natural drugs and over-the-counter drugs administration of the Ministry of health of Canada Prior to that, domestic enterprises such as Guangzhou Qixing Pharmaceutical Co., Ltd., Guangzhou Xiangxue Pharmaceutical Co., Ltd and Tianshi Pharmaceutical Group Co., Ltd also had relevant Chinese medicine products listed and sold in Canada, showing us another dawn of Chinese medicine going abroad And yesterday (February 15), Guangyao Group signed a contract with fortune magazine on the strategic cooperation of 2017 Fortune Global Forum (Guangzhou) This time, Guangyao group was invited as the strategic partner of 2017 Fortune Global Forum, and will host the "medical health sub forum" Guangyao group, as one of the leading pharmaceutical companies in China, is also accelerating the pace of internationalization with its practical actions Li Chuyuan, chairman of Guangyao group, said in an interview after the meeting that cooperation between Guangyao group and fortune forum is part of the company's internationalization strategy Specifically, through cooperation with fortune magazine, we can speed up the implementation of the internationalization strategy of Guangyao group with the help of the influence of fortune group, and let the products of Wanglaoji herbal tea and Baiyunshan drinking water of Guangyao group go out as early as possible According to the data of China Medical Insurance chamber of Commerce, in 2016, China's import and export of medical and health care products reached 103.4 billion US dollars, an increase of 0.73% year on year If we exclude the influence of exchange rate and convert it into RMB, in 2016, the foreign trade of medicine increased by 7.12%, the export by 4.41%, and the import by 10.42%, leading the overall level of China's foreign trade Although in 2016, the import and export of Pharmaceutical Foreign Trade entered a period of low-speed growth, influenced by many factors such as weak demand of major external economies, lack of power in emerging markets, and increasingly fierce price competition, we see that the structure of pharmaceutical export has been further optimized, the pace of internationalization of enterprises has been accelerated, new development momentum is accumulating, and the overall development situation of pharmaceutical foreign trade is still good At present, a large number of Chinese pharmaceutical companies are actively moving towards the international market while vigorously developing the domestic market We are looking forward to the day when local pharmaceutical companies like Huawei will emerge and become famous all over the world! Attachment: 2016 pharmaceutical foreign trade list